I absolutely agree with all of the positive comments about today's CC. So I gather that NP decided not to further supplement the BTD application by including the preliminary data from patient #5 (thereby avoiding a potential re-start of the 60 day review period); hopefully the FDA decides it already has enough data from the other patients to issue an approval!